Arkolith/Insider Trading/JNCE/Form 4

Salter-Cid Luisa

DirectorJounce Therapeutics, Inc. (JNCE) · full profile →Form 4 · filed May 4, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
0 non-derivative · 3 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 3, 2023Disposed to issuer(D)8K——0
May 3, 2023Disposed to issuer(D)20K——0
May 3, 2023Disposed to issuer(D)31K——0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001640455-23-000114) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML